enVVeno Medical received the first-ever FDA Investigational Device Exemption for a pivotal U.S. study of its enVVe non-surgical replacement venous valve. This approval allows the company to evaluate safety and efficacy in patients with severe Deep Venous Insufficiency under a regulated clinical protocol.

CEO Robert Berman participated in a Virtual Investor "What This Means" segment to discuss the IDE approval’s impact on clinical development and long-term strategy. The segment, now available online, delved into enrollment goals, study design and potential regulatory milestones.

The enVVe system features a tissue-based, one-way valve delivered via catheter under light sedation without overnight hospitalization. The device is designed to restore blood flow in the leg and back to the heart, addressing the needs of an estimated 3 million U.S. patients suffering from chronic venous disease.

With IDE approval in hand, enVVeno plans to initiate a multicenter pivotal trial across selected U.S. sites, targeting initial patient enrollment in the coming months. Key upcoming milestones include first patient implant, interim safety analysis and a future pre-market approval submission.